# Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences-39ba28ab
Ticker: ZNTL
Company: Zentalis
Source: Zentalis
Published: 2026-05-13 20:05 EST
## Summary

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage...

## Article Body
Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:

H.C. Wainwright 4 th Annual BioConnect Conference at Nasdaq, New York, NY. Fireside discussion, May 19, 2026, 2:30p.m. ET.

Stifel 2026 Virtual Oncology Forum, Virtual. Fireside discussion, May 20, 2026, 4:30p.m. ET.

TD Cowen 6 th Annual Oncology Innovation Summit: Insights for ASCO & EHA, Virtual. Fireside discussion, May 26, 2026, 10:00a.m. ET.

Jefferies Global Healthcare Conference, New York, NY. Fireside discussion, June 3, 2026, 3:45p.m. ET.

Access to a live webcast of each of the H.C. Wainwright, Stifel, TD Cowen, and Jefferies events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website .

About Zentalis Pharmaceuticals Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.

For more information, please visit www.zentalis.com . Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals

ZENTALIS ® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.

Contact: Aron Feingold VP, Investor Relations & Corporate Communications ir@zentalis.com
## Recent Company News
- 2026-07-17 20:15 EST — [Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-at-the-european-society-for-medical-oncology-7b982012) — Source: Zentalis
- 2026-06-01 21:00 EST — [Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5-1f326240) — Source: Zentalis
- 2026-05-27 20:05 EST — [Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy](https://biopharmsignal.com/news/ZNTL/zentalis-strengthens-commercial-leadership-with-appointments-of-shannon-campbell-34c7acfb) — Source: Zentalis
- 2026-05-21 21:39 EST — [Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-present-phase-1b-muir-trial-data-showing-encouraging-6d0f0eb0) — Source: Zentalis
- 2026-05-13 20:05 EST — [Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ZNTL/zentalis-pharmaceuticals-to-participate-in-upcoming-investor-conferences-39ba28ab) — Source: Zentalis
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)